Advanced

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.

Kofoed Damm, Jesper LU ; Gordon, Sandra LU ; Ehinger, Mats LU ; Jerkeman, Mats LU ; Gullberg, Urban LU ; Hultquist, Anne LU and Drott, Kristina LU (2015) In Experimental hematology & oncology 4(4).
Abstract
Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have been proposed as potential new therapies for lymphoid malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma for which standard first line treatment is the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) combined with the monoclonal anti-CD20 antibody rituximab (R-CHOP). The HDACi valproate, which has for long been utilized in anti-convulsive therapy, has been shown to sensitize to chemotherapy in vitro. Valproate upregulates expression of CD20 in lymphoma cell lines; therefore, 48 hour pre-treatment with valproate before first line R-CHOP in DLBCL stages II-IV is evaluated in the... (More)
Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have been proposed as potential new therapies for lymphoid malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma for which standard first line treatment is the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) combined with the monoclonal anti-CD20 antibody rituximab (R-CHOP). The HDACi valproate, which has for long been utilized in anti-convulsive therapy, has been shown to sensitize to chemotherapy in vitro. Valproate upregulates expression of CD20 in lymphoma cell lines; therefore, 48 hour pre-treatment with valproate before first line R-CHOP in DLBCL stages II-IV is evaluated in the phase I clinical trial VALFRID; Valproate as First line therapy in combination with Rituximab and CHOP in Diffuse large B-cell lymphoma. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Experimental hematology & oncology
volume
4
issue
4
publisher
BioMed Central
external identifiers
  • pmid:25973343
  • scopus:84978026215
ISSN
2162-3619
DOI
10.1186/2162-3619-4-4
language
English
LU publication?
yes
id
33f0e83e-3a86-45b6-9418-25dc13987248 (old id 5453247)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25973343?dopt=Abstract
date added to LUP
2015-06-04 19:35:10
date last changed
2017-06-25 04:07:37
@article{33f0e83e-3a86-45b6-9418-25dc13987248,
  abstract     = {Epigenetic code modifications by histone deacetylase inhibitors (HDACi) have been proposed as potential new therapies for lymphoid malignancies. Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma for which standard first line treatment is the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) combined with the monoclonal anti-CD20 antibody rituximab (R-CHOP). The HDACi valproate, which has for long been utilized in anti-convulsive therapy, has been shown to sensitize to chemotherapy in vitro. Valproate upregulates expression of CD20 in lymphoma cell lines; therefore, 48 hour pre-treatment with valproate before first line R-CHOP in DLBCL stages II-IV is evaluated in the phase I clinical trial VALFRID; Valproate as First line therapy in combination with Rituximab and CHOP in Diffuse large B-cell lymphoma.},
  author       = {Kofoed Damm, Jesper and Gordon, Sandra and Ehinger, Mats and Jerkeman, Mats and Gullberg, Urban and Hultquist, Anne and Drott, Kristina},
  issn         = {2162-3619},
  language     = {eng},
  number       = {4},
  publisher    = {BioMed Central},
  series       = {Experimental hematology & oncology},
  title        = {Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.},
  url          = {http://dx.doi.org/10.1186/2162-3619-4-4},
  volume       = {4},
  year         = {2015},
}